Gan & Lee Pharmaceuticals. (603087.SS)
CNY 45.54
(0.35%)
CNY 45.54
(0.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.58 Billion | 1.71 Billion | 3.61 Billion | 3.36 Billion | 2.89 Billion | 2.38 Billion |
| Cost of Revenue | 724.7 Million | 405.8 Million | 396.11 Million | 306.65 Million | 237.97 Million | 187.86 Million |
| Gross Profit | 1.85 Billion | 1.3 Billion | 3.21 Billion | 3.05 Billion | 2.65 Billion | 2.19 Billion |
| Operating Expenses | 1.6 Billion | 1.87 Billion | 1.75 Billion | 1.62 Billion | 1.29 Billion | 1.07 Billion |
| Selling, General and Administrative Expenses | 1.12 Billion | 1.17 Billion | 1.1 Billion | 1.01 Billion | 862.41 Million | 779.73 Million |
| Research and Development Expenses | 501.02 Million | 562.46 Million | 474.58 Million | 419.98 Million | 235.55 Million | 142.99 Million |
| Other Expenses | -26.63 Million | 137.2 Million | 181.16 Million | 190.66 Million | 201.33 Million | -563.51 Thousand |
| Cost and Expenses | 2.29 Billion | 2.27 Billion | 2.15 Billion | 1.93 Billion | 1.53 Billion | 1.26 Billion |
| Operating Income | 315.28 Million | -564.27 Million | 1.69 Billion | 1.45 Billion | 1.39 Billion | 1.11 Billion |
| Interest Expense | 1.35 Million | 776 Thousand | 964.73 Thousand | 3.82 Million | 3.39 Million | - |
| Income Tax Expense | -34.09 Million | -142.95 Million | 243.25 Million | 214.75 Million | 230.18 Million | 179.55 Million |
| Earnings before Tax | 306.14 Million | -582.47 Million | 1.69 Billion | 1.44 Billion | 1.39 Billion | 1.11 Billion |
| Net Income | 340.06 Million | -439.51 Million | 1.45 Billion | 1.23 Billion | 1.16 Billion | 933.96 Million |
| Earnings Per Share Basic | 0.60 | -0.78 | 2.59 | 2.19 | 2.08 | 1.85 |
| Earnings Per Share Diluted | 0.60 | -0.78 | 2.59 | 2.19 | 2.08 | 1.85 |
| Weighted Average Shares Outstanding | 566.78 Million | 561.54 Million | 561.54 Million | 561.54 Million | 561.54 Million | 504.84 Million |
| Weighted Average Shares Outstanding (Diluted) | 566.78 Million | 561.54 Million | 561.54 Million | 561.54 Million | 561.54 Million | 504.84 Million |
| Gross Margin | 0.72 | 0.76 | 0.89 | 0.91 | 0.92 | 0.92 |
| EBIT Margin | 0.21 | -0.11 | 0.54 | 0.48 | 0.52 | 0.52 |
| Profit Margin | 0.13 | -0.26 | 0.40 | 0.37 | 0.40 | 0.39 |
| EBITDA | 531.95 Million | -377.98 Million | 1.88 Billion | 1.58 Billion | 1.47 Billion | 1.21 Billion |
| Earnings Before Tax Margin | 0.12 | -0.33 | 0.47 | 0.43 | 0.48 | 0.47 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 930.11 Million | 746.38 Million | 554.06 Million | 2.58 Billion | 696.03 Million | 675.9 Million |
| Cost of Revenue | 204.14 Million | 223.29 Million | 152.24 Million | 795.82 Million | 240.79 Million | 158.53 Million |
| Gross Profit | 725.97 Million | 523.09 Million | 401.81 Million | 1.78 Billion | 455.24 Million | 517.37 Million |
| Operating Expenses | 547.76 Million | 429.27 Million | 403.45 Million | 1.6 Billion | 480.88 Million | 389.86 Million |
| Selling, General and Administrative Expenses | 690.46 Million | 306.74 Million | 270.38 Million | - | 323.69 Million | 343.33 Million |
| Research and Development Expenses | 136.96 Million | 122.49 Million | 133.12 Million | - | 120.71 Million | 107.98 Million |
| Other Expenses | -279.66 Million | -32.8 Thousand | 49.61 Thousand | -26.63 Million | -36.47 Million | -1.84 Million |
| Cost and Expenses | 751.9 Million | 652.56 Million | 555.7 Million | 2.4 Billion | 721.67 Million | 548.39 Million |
| Operating Income | 222.9 Million | 93.81 Million | -1.63 Million | 180.03 Million | -25.64 Million | 153.17 Million |
| Interest Expense | - | - | - | 551.7 Thousand | - | - |
| Income Tax Expense | 14.39 Million | 24.39 Million | 17.55 Million | -34.09 Million | -78.63 Million | 19 Million |
| Earnings before Tax | 222.75 Million | 227.29 Million | 113.56 Million | 306.14 Million | -4.88 Million | 151.32 Million |
| Net Income | 208.36 Million | 202.89 Million | 96 Million | 340.06 Million | 73.59 Million | 132.32 Million |
| Earnings Per Share Basic | 0.35 | 0.34 | 0.16 | - | 0.13 | 0.24 |
| Earnings Per Share Diluted | 0.35 | 0.34 | 0.16 | - | 0.13 | 0.24 |
| Weighted Average Shares Outstanding | 591.1 Million | 591.23 Million | 590.04 Million | 566.78 Million | 586.6 Million | 561.54 Million |
| Weighted Average Shares Outstanding (Diluted) | 591.1 Million | 591.23 Million | 590.04 Million | 566.78 Million | 586.6 Million | 561.54 Million |
| Gross Margin | 0.78 | 0.70 | 0.73 | 0.69 | 0.65 | 0.77 |
| EBIT Margin | -0.07 | 0.21 | -0.15 | - | 0.05 | 0.11 |
| Profit Margin | 0.22 | 0.27 | 0.17 | 0.13 | 0.11 | 0.20 |
| EBITDA | -62.16 Million | 156.37 Million | -81.47 Million | - | 31.77 Million | 72.79 Million |
| Earnings Before Tax Margin | 0.24 | 0.13 | -0.00 | 0.07 | -0.04 | 0.23 |
NPAB
000402
VOIS
300070
JCYCF
POMO3